Bionano Genomics, Inc.(BNGO)Earnings, Financials & Key Ratios
BNGO•NASDAQ
$1.27
$14M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryLife Science Instruments and Sequencing Tools
AboutBionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.Show more
- Revenue$29M-7.4%
- EBITDA-$33M+62.9%
- Net Income-$26M+76.4%
- EPS (Diluted)-4.85+94.5%
- Gross Margin49.39%+3899.8%
- EBITDA Margin-116.95%+59.9%
- Operating Margin-116.95%+65.4%
- Net Margin-92.59%+74.6%
- ROE-66.15%+61.2%
- ROIC-49.1%+33.5%
- Debt/Equity0.16-79.8%
BNGO Key Insights
Bionano Genomics, Inc. (BNGO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 27.4%
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BNGO Price & Volume
Bionano Genomics, Inc. (BNGO) stock price & volume — 10-year historical chart
Loading chart...
BNGO Growth Metrics
Bionano Genomics, Inc. (BNGO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years27.37%
3 Years0.84%
TTM-7.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM76.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM94.85%
Return on Capital
10 Years-160.16%
5 Years-80.17%
3 Years-106.98%
Last Year-74.11%
BNGO Peer Comparison
Bionano Genomics, Inc. (BNGO) competitors in Life Science Instruments and Sequencing Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 3.29B | 41.19 | 50.23 | 16.01% | 16.25% | 6.86% | 0.03 | |
 TMO | 175.76B | 472.95 | 26.66 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 123.8B | 174.92 | 34.71 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare BNGO vs Peers
Bionano Genomics, Inc. (BNGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BNGO Income Statement
Bionano Genomics, Inc. (BNGO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 9.51M | 12M | 10.13M | 8.5M | 17.98M | 27.8M | 36.12M | 30.78M | 28.51M |
| Revenue Growth % | 39.93% | 26.26% | -15.59% | -16.06% | 111.47% | 54.62% | 29.9% | -14.79% | -7.37% |
| Cost of Goods Sold | 6.03M | 8.71M | 6.77M | 5.73M | 14.11M | 21.86M | 26.55M | 30.4M | 14.43M |
| COGS % of Revenue | 63.45% | 72.59% | 66.82% | 67.39% | 78.45% | 78.62% | 73.51% | 98.77% | 50.61% |
| Gross Profit | 3.47M▲ 0% | 3.29M▼ 5.3% | 3.36M▲ 2.2% | 2.77M▼ 17.5% | 3.87M▲ 39.7% | 5.95M▲ 53.5% | 9.57M▲ 60.9% | 380K▼ 96.0% | 14.08M▲ 3605.0% |
| Gross Margin % | 36.55% | 27.41% | 33.18% | 32.61% | 21.55% | 21.38% | 26.49% | 1.23% | 49.39% |
| Gross Profit Growth % | 8.1% | -5.33% | 2.19% | -17.5% | 39.7% | 53.46% | 60.91% | -96.03% | 3605% |
| Operating Expenses | 26.09M | 23.7M | 29.24M | 41.32M | 80.97M | 137.64M | 224.81M | 104.36M | 46.52M |
| OpEx % of Revenue | 274.47% | 197.53% | 288.62% | 485.99% | 450.34% | 495.08% | 622.47% | 339.11% | 163.2% |
| Selling, General & Admin | 14.08M | 14.22M | 20.16M | 0 | 58.49M | 88.6M | 94.96M | 51.85M | 35.15M |
| SG&A % of Revenue | 148.13% | 118.5% | 198.98% | - | 325.29% | 318.67% | 262.93% | 168.49% | 123.3% |
| Research & Development | 12.01M | 9.48M | 9.08M | 10.26M | 22.48M | 49.05M | 54.03M | 24.8M | 11.37M |
| R&D % of Revenue | 126.35% | 79.03% | 89.65% | 120.62% | 125.05% | 176.42% | 149.61% | 80.59% | 39.9% |
| Other Operating Expenses | 0 | 0 | 0 | 31.07M | 0 | 0 | 75.82M | 27.7M | 0 |
| Operating Income | -23.22M▲ 0% | -20.42M▲ 12.1% | -25.87M▼ 26.7% | -38.55M▼ 49.0% | -77.1M▼ 100.0% | -131.7M▼ 70.8% | -215.25M▼ 63.4% | -103.98M▲ 51.7% | -33.34M▲ 67.9% |
| Operating Margin % | -244.28% | -170.12% | -255.44% | -453.38% | -428.79% | -473.7% | -595.98% | -337.87% | -116.95% |
| Operating Income Growth % | -9.69% | 12.08% | -26.74% | -48.99% | -100% | -70.81% | -63.44% | 51.69% | 67.94% |
| EBITDA | -21.71M | -19.09M | -24.75M | -37.07M | -73.73M | -121.6M | -201.54M | -89.76M | -33.34M |
| EBITDA Margin % | -228.46% | -159.11% | -244.31% | -435.99% | -410.05% | -437.38% | -558.03% | -291.65% | -116.95% |
| EBITDA Growth % | -8.28% | 12.07% | -29.6% | -49.8% | -98.89% | -64.92% | -65.74% | 55.46% | 62.86% |
| D&A (Non-Cash Add-back) | 1.5M | 1.32M | 1.13M | 1.48M | 3.37M | 10.1M | 13.71M | 14.23M | 0 |
| EBIT | -22.76M | -17.1M | -27.51M | -37.05M | -77.22M | -130.41M | -227.31M | -111.69M | 0 |
| Net Interest Income | -590.93K | -1.38M | -2.29M | -2.52M | -691K | 1.21M | -1.81M | 1.81M | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 236K | 1.51M | 3.31M | 2.1M | 1.11M |
| Interest Expense | 590.93K | 1.38M | 2.29M | 2.52M | 927K | 298K | 5.12M | 289K | 0 |
| Other Income/Expense | -128K | 1.93M | -3.92M | -2.53M | -1.05M | 986K | -17.19M | -8M | 7.01M |
| Pretax Income | -23.35M▲ 0% | -18.48M▲ 20.8% | -29.79M▼ 61.2% | -41.08M▼ 37.9% | -78.15M▼ 90.3% | -130.71M▼ 67.3% | -232.43M▼ 77.8% | -111.98M▲ 51.8% | -26.33M▲ 76.5% |
| Pretax Margin % | -245.63% | -154% | -294.13% | -483.09% | -434.64% | -470.15% | -643.57% | -363.87% | -92.35% |
| Income Tax | 18.55K | 15.51K | 21.05K | 29K | -5.72M | 1.88M | 62K | 33K | -67K |
| Effective Tax Rate % | -0.08% | -0.08% | -0.07% | -0.07% | 7.32% | -1.44% | -0.03% | -0.03% | 0.25% |
| Net Income | -23.37M▲ 0% | -18.5M▲ 20.8% | -29.82M▼ 61.2% | -41.11M▼ 37.9% | -72.44M▼ 76.2% | -132.6M▼ 83.1% | -232.49M▼ 75.3% | -112.02M▲ 51.8% | -26.39M▲ 76.4% |
| Net Margin % | -245.82% | -154.13% | -294.34% | -483.43% | -402.84% | -476.93% | -643.74% | -363.98% | -92.59% |
| Net Income Growth % | -23.96% | 20.84% | -61.19% | -37.87% | -76.22% | -83.06% | -75.34% | 51.82% | 76.44% |
| Net Income (Continuing) | -23.37M | -18.5M | -29.82M | -41.11M | -72.44M | -132.6M | -232.49M | -112.02M | -26.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00▲ 0% | -94089.60▲ 0% | -71662.20▲ 23.8% | -14194.80▲ 80.2% | -157.02▲ 98.9% | -267.71▼ 70.5% | -408.60▼ 52.6% | -88.13▲ 78.4% | -4.85▲ 94.5% |
| EPS Growth % | - | - | 23.84% | 80.19% | 98.89% | -70.49% | -52.63% | 78.43% | 94.5% |
| EPS (Basic) | 0.00 | -94089.60 | -71662.20 | -14194.80 | -157.02 | -267.71 | -408.48 | -88.13 | -4.85 |
| Diluted Shares Outstanding | 0 | 201 | 424 | 177.23K | 470.53K | 491.66K | 580.55K | 1.9M | 5.45M |
| Basic Shares Outstanding | 0 | 201 | 424 | 177.23K | 470.53K | 491.66K | 580.38K | 1.9M | 5.45M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BNGO Balance Sheet
Bionano Genomics, Inc. (BNGO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.14M | 23.03M | 28.26M | 46.79M | 272.41M | 157.3M | 140.12M | 39.49M | 45.39M |
| Cash & Short-Term Investments | 1.02M | 16.52M | 17.31M | 38.45M | 250.61M | 113.19M | 66.77M | 9.47M | 13.26M |
| Cash Only | 1.02M | 16.52M | 17.31M | 38.45M | 24.57M | 5.09M | 17.95M | 9.17M | 2.99M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 226.04M | 108.09M | 48.82M | 302K | 10.27M |
| Accounts Receivable | 3.35M | 4.51M | 6.33M | 2.77M | 5.32M | 7.5M | 9.66M | 4.77M | 5.2M |
| Days Sales Outstanding | 128.73 | 137.3 | 228.23 | 119.12 | 108.01 | 98.41 | 97.64 | 56.62 | 66.58 |
| Inventory | 1.69M | 1.07M | 3.44M | 3.31M | 12.39M | 29.76M | 22.89M | 11.12M | 5.45M |
| Days Inventory Outstanding | 102.51 | 44.77 | 185.71 | 211.16 | 320.5 | 496.99 | 314.71 | 133.54 | 137.81 |
| Other Current Assets | 550.06K | 458.82K | 457.06K | 462K | 1.38M | 2.41M | 36.09M | 12.32M | 21.48M |
| Total Non-Current Assets | 3.01M | 1.78M | 1.95M | 13.66M | 104.69M | 150.2M | 74.28M | 37.18M | 28.2M |
| Property, Plant & Equipment | 3.01M | 1.78M | 1.95M | 4.91M | 20.93M | 28.96M | 32.48M | 24.32M | 21.16M |
| Fixed Asset Turnover | 3.16x | 6.75x | 5.20x | 1.73x | 0.86x | 0.96x | 1.11x | 1.27x | 1.35x |
| Goodwill | 0 | 0 | 0 | 7.17M | 56.16M | 77.29M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 1.48M | 26.84M | 41.14M | 33.97M | 9.71M | 4.34M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 103K | 749K | 2.81M | 7.83M | 3.15M | 2.69M |
| Total Assets | 10.15M▲ 0% | 24.8M▲ 144.5% | 30.21M▲ 21.8% | 60.45M▲ 100.1% | 377.1M▲ 523.8% | 307.5M▼ 18.5% | 214.4M▼ 30.3% | 76.67M▼ 64.2% | 73.58M▼ 4.0% |
| Asset Turnover | 0.94x | 0.48x | 0.34x | 0.14x | 0.05x | 0.09x | 0.17x | 0.40x | 0.39x |
| Asset Growth % | -31.39% | 144.48% | 21.79% | 100.11% | 523.82% | -18.46% | -30.28% | -64.24% | -4.03% |
| Total Current Liabilities | 16.65M | 4.52M | 26.37M | 8.95M | 21.84M | 35.88M | 100.03M | 37.34M | 22.94M |
| Accounts Payable | 2.3M | 1.35M | 2.7M | 2.93M | 10.77M | 12.53M | 10.38M | 6.96M | 5.59M |
| Days Payables Outstanding | 139.39 | 56.64 | 145.56 | 186.64 | 278.63 | 209.31 | 142.76 | 83.6 | 141.41 |
| Short-Term Debt | 6.73M | 0 | 20.08M | 0 | 0 | 0 | 69.8M | 20.36M | 946K |
| Deferred Revenue (Current) | 211.7K | 271K | 357.49K | 416K | 1.51M | 888K | 800K | 1.13M | 0 |
| Other Current Liabilities | 3.9M | 2.13M | 2.07M | 3.36M | 4.53M | 16.38M | 13.96M | 3M | 22M |
| Current Ratio | 0.43x | 5.09x | 1.07x | 5.23x | 12.47x | 4.38x | 1.40x | 1.06x | 1.98x |
| Quick Ratio | 0.33x | 4.85x | 0.94x | 4.86x | 11.91x | 3.55x | 1.17x | 0.76x | 1.74x |
| Cash Conversion Cycle | 91.85 | 125.44 | 268.38 | 143.64 | 149.88 | 386.09 | 269.59 | 106.56 | 62.99 |
| Total Non-Current Liabilities | 43.72M | 10.14M | 227.13K | 16.42M | 18.14M | 22.22M | 18.22M | 3.95M | 6.22M |
| Long-Term Debt | 0 | 9.03M | 0 | 16.32M | 0 | 0 | 0 | 0 | 5.97M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 8.93M | 9.12M | 7.17M | 3.68M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 43.58M | 808.37K | 44.48K | 0 | 9.07M | 12.97M | 10.89M | 0 | 249K |
| Total Liabilities | 60.37M | 14.67M | 26.59M | 25.37M | 39.98M | 58.1M | 118.25M | 41.3M | 29.16M |
| Total Debt | 6.73M | 9.03M | 20.08M | 16.32M | 10.7M | 11.67M | 79.41M | 27.3M | 6.92M |
| Net Debt | 5.71M | -7.49M | 2.77M | -22.12M | -13.88M | 6.58M | 61.47M | 18.12M | 3.92M |
| Debt / Equity | - | 0.89x | 5.56x | 0.47x | 0.03x | 0.05x | 0.83x | 0.77x | 0.16x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -39.29x | -14.78x | -11.32x | -15.30x | -83.17x | -441.94x | -42.05x | -359.80x | - |
| Total Equity | -50.23M▲ 0% | 10.14M▲ 120.2% | 3.61M▼ 64.4% | 35.08M▲ 870.8% | 337.12M▲ 860.9% | 249.4M▼ 26.0% | 96.16M▼ 61.4% | 35.38M▼ 63.2% | 44.42M▲ 25.6% |
| Equity Growth % | -84.26% | 120.18% | -64.35% | 870.8% | 860.94% | -26.02% | -61.44% | -63.21% | 25.58% |
| Book Value per Share | - | 50556.57 | 8515.47 | 197.95 | 716.46 | 507.26 | 165.63 | 18.59 | 8.16 |
| Total Shareholders' Equity | -50.23M | 10.14M | 3.61M | 35.08M | 337.12M | 249.4M | 96.16M | 35.38M | 44.42M |
| Common Stock | 8 | 1K | 3.43K | 19K | 29K | 3K | 0 | 0 | 1K |
| Retained Earnings | -54.27M | -72.76M | -102.58M | -143.68M | -216.12M | -348.71M | -581.21M | -693.23M | -719.62M |
| Treasury Stock | -4.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3.92M | -5.16M | 0 | 0 | -539K | -1.12M | 23K | 27K | 17K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNGO Cash Flow Statement
Bionano Genomics, Inc. (BNGO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -20.82M | -19.94M | -29.53M | -38.31M | -71.93M | -124.82M | -125.18M | -68.92M | -16.34M |
| Operating CF Margin % | -219.02% | -166.19% | -291.52% | -450.59% | -400.02% | -448.95% | -346.61% | -223.95% | -57.33% |
| Operating CF Growth % | 11.4% | 4.2% | -48.06% | -29.75% | -87.73% | -73.53% | -0.29% | 44.94% | 76.28% |
| Net Income | -23.37M | -18.5M | -29.82M | -41.11M | -72.44M | -132.6M | -232.49M | -112.02M | -26.39M |
| Depreciation & Amortization | 1.5M | 1.32M | 1.13M | 1.48M | 3.37M | 9.84M | 13.91M | 14.23M | 9.73M |
| Stock-Based Compensation | 382.83K | 1.31M | 1.35M | 1.55M | 9.72M | 22.42M | 15.18M | 9.74M | 4.53M |
| Deferred Taxes | 479.01K | -2.46M | 1.9M | 0 | -5.78M | 1.76M | 0 | 0 | 0 |
| Other Non-Cash Items | 96.58K | 750.47K | 883.27K | 3.2M | 848K | 1.7M | 92.99M | 14.73M | -4.21M |
| Working Capital Changes | 85.1K | -2.37M | -4.97M | -3.44M | -7.65M | -27.94M | -14.77M | 4.4M | 0 |
| Change in Receivables | -1.77M | -900.12K | -2.37M | 2.09M | -493K | -2.25M | -2.3M | 4.14M | -448K |
| Change in Inventory | -336.05K | -418.98K | -3.64M | -4.2M | -15.93M | -23.68M | -4.15M | -587K | 4.92M |
| Change in Payables | 1.54M | -954.38K | 1.36M | -1.81M | 6.78M | 1.95M | -2M | -3.42M | -1.37M |
| Cash from Investing | -1.02M | -331.72K | -61.06K | -2.45M | -278.06M | 82.77M | 24.16M | 73.84M | -12.75M |
| Capital Expenditures | -1.02M | -331.72K | -61.06K | 0 | -1.46M | -3.2M | -1.69M | -103K | 0 |
| CapEx % of Revenue | 10.71% | 2.76% | 0.6% | - | 8.12% | 11.51% | 4.68% | 0.33% | - |
| Acquisitions | 0 | 0 | 0 | -2.45M | -49.09M | -31.34M | 96K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -607K | 618K | 0 | 0 | 0 |
| Cash from Financing | 17.61M | 35.78M | 30.38M | 61.9M | 336.11M | 23.01M | 113.81M | -13.69M | 24.04M |
| Debt Issued (Net) | 0 | 16.38M | 9.82M | -4.72M | -15.01M | -36K | 70.95M | -48.06M | 0 |
| Equity Issued (Net) | 17.59M | 19.39M | 19.56M | 39.93M | 342.71M | 23.13M | 57.7M | 44.43M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 14.29K | 3.5K | 1M | 26.69M | 8.4M | -85K | -14.84M | -10.06M | 24.04M |
| Net Change in Cash | -4.23M▲ 0% | 15.5M▲ 466.6% | 788.64K▼ 94.9% | 21.14M▲ 2580.3% | -13.88M▼ 165.7% | -19.08M▼ 37.5% | 12.86M▲ 167.4% | -8.78M▼ 168.3% | -5.06M▲ 42.3% |
| Free Cash Flow | -21.84M▲ 0% | -20.28M▲ 7.1% | -29.59M▼ 45.9% | -38.31M▼ 29.5% | -73.39M▼ 91.5% | -128.12M▼ 74.6% | -126.87M▲ 1.0% | -69.03M▲ 45.6% | -16.34M▲ 76.3% |
| FCF Margin % | -229.73% | -168.95% | -292.12% | -450.59% | -408.14% | -460.82% | -351.29% | -224.28% | -57.33% |
| FCF Growth % | 12.12% | 7.14% | -45.94% | -29.48% | -91.54% | -74.58% | 0.97% | 45.59% | 76.32% |
| FCF per Share | - | -101117.44 | -69728.55 | -216.19 | -155.97 | -260.58 | -218.54 | -36.28 | -3.00 |
| FCF Conversion (FCF/Net Income) | 0.89x | 1.08x | 0.99x | 0.93x | 0.99x | 0.94x | 0.54x | 0.62x | 0.62x |
| Interest Paid | 0 | 0 | 0 | 1.25M | 1.91M | 298K | 1.65M | 10.65M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNGO Key Ratios
Bionano Genomics, Inc. (BNGO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -182.46% | -433.64% | -212.46% | -38.92% | -45.21% | -134.56% | -170.33% | -66.15% |
| Return on Invested Capital (ROIC) | - | - | -579.1% | -429.75% | -298.92% | -34.4% | -34.11% | -78.06% | -73.88% | -49.1% |
| Gross Margin | 47.32% | 36.55% | 27.41% | 33.18% | 32.61% | 21.55% | 21.38% | 26.49% | 1.23% | 49.39% |
| Net Margin | -277.48% | -245.82% | -154.13% | -294.34% | -483.43% | -402.84% | -476.93% | -643.74% | -363.98% | -92.59% |
| Debt / Equity | - | - | 0.89x | 5.56x | 0.47x | 0.03x | 0.05x | 0.83x | 0.77x | 0.16x |
| Interest Coverage | -45.03x | -39.29x | -14.78x | -11.32x | -15.30x | -83.17x | -441.94x | -42.05x | -359.80x | - |
| FCF Conversion | 1.25x | 0.89x | 1.08x | 0.99x | 0.93x | 0.99x | 0.94x | 0.54x | 0.62x | 0.62x |
| Revenue Growth | - | 39.93% | 26.26% | -15.59% | -16.06% | 111.47% | 54.62% | 29.9% | -14.79% | -7.37% |
BNGO Frequently Asked Questions
Bionano Genomics, Inc. (BNGO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bionano Genomics, Inc. (BNGO) reported $28.5M in revenue for fiscal year 2025. This represents a 320% increase from $6.8M in 2016.
Bionano Genomics, Inc. (BNGO) saw revenue decline by 7.4% over the past year.
Bionano Genomics, Inc. (BNGO) reported a net loss of $26.4M for fiscal year 2025.
Dividend & Returns
Bionano Genomics, Inc. (BNGO) has a return on equity (ROE) of -66.2%. Negative ROE indicates the company is unprofitable.
Bionano Genomics, Inc. (BNGO) had negative free cash flow of $16.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More BNGO
Bionano Genomics, Inc. (BNGO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates